.Pharmacolibrary.Drugs.ATC.M.M04AA03

Information

Febuxostat is a non-purine selective inhibitor of xanthine oxidase, used primarily for the treatment of chronic hyperuricemia in patients with gout. It is an orally administered medication approved in many countries, though its use may be restricted in some regions due to cardiovascular concerns.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.

References

1. Liu, XX, et al., & Wang, SL (2012). Pharmacokinetics of febuxostat in healthy Chinese volunteers. Arzneimittel-Forschung 62(10) 463–469. DOI:10.1055/s-0032-1321847 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22956350

2. Lin, M, et al., & Wu, L (2017). Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. Drug metabolism and pharmacokinetics 32(1) 77–84. DOI:10.1016/j.dmpk.2016.08.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28131654

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)